Literature DB >> 18503615

alpha-Hemoglobin stabilizing protein is not a suitable marker for a screening test for variant Creutzfeldt-Jakob disease.

Nigel E J Appleford1, Kim Wilson, Fiona Houston, Lesley J Bruce, Alex Morrison, Matthew Bishop, Kevin Chalmers, Gino Miele, Edwin Massey, Chris Prowse, Jean Manson, Robert G Will, Michael Clinton, Ian MacGregor, David J Anstee.   

Abstract

BACKGROUND: A test is needed to identify blood donors who are in the preclinical phase of variant Creutzfeldt-Jakob disease (CJD). alpha-Hemoglobin stabilizing protein (AHSP; syn. ERAF, EDRF) transcript levels are reduced in the blood of mice incubating transmissible spongiform encephalopathy. STUDY DESIGN AND METHODS: Quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay were used to measure AHSP transcript and protein levels in normal blood donors, patients with CJD, and patients with other neuronal and hematologic diseases. Temporal AHSP expression was measured in sheep incubating bovine spongiform encephalopathy (BSE).
RESULTS: Quantitation of AHSP in peripheral blood from normal blood donors revealed that protein levels, but not transcript levels, are influenced by sex with higher levels found in males, suggesting posttranslational regulation involving the product of an X-linked gene. When AHSP mRNA and protein levels were quantitated in peripheral blood from patients with variant and sporadic CJD, no consistent differences from normal were found. Serial quantitation of AHSP in individual BSE-infected sheep did not reveal any disease-related changes.
CONCLUSION: We conclude that quantitation of AHSP is not likely to be useful for detection of preclinical prion disease in man.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503615     DOI: 10.1111/j.1537-2995.2008.01759.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2).

Authors:  Emile van den Akker; Timothy J Satchwell; Stephanie Pellegrin; Joanna F Flatt; Michel Maigre; Geoff Daniels; Jean Delaunay; Lesley J Bruce; Ashley M Toye
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

2.  Prion Protein-Hemin Interaction Upregulates Hemoglobin Synthesis: Implications for Cerebral Hemorrhage and Sporadic Creutzfeldt-Jakob Disease.

Authors:  Ajai K Tripathi; Neena Singh
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

3.  Factors affecting the accuracy of urine-based biomarkers of BSE.

Authors:  Margot Plews; Lise Lamoureux; Sharon Lr Simon; Catherine Graham; Viola Ruddat; Stefanie Czub; J David Knox
Journal:  Proteome Sci       Date:  2011-02-07       Impact factor: 2.480

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.